rilotumumab

Known as: Anti-HGF Monoclonal Antibody AMG 102, Fully Human Anti-HGF Monoclonal Antibody AMG 102 
A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
024620092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The antibody rilotumumab, which has been tested in multiple Phase 2 and Phase 3 trials, has been reported to neutralize… (More)
Is this relevant?
2015
2015
Background:Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
PURPOSE Rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor. In a randomized phase II… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is… (More)
Is this relevant?
2014
2014
PURPOSE Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody (mAb), has demonstrated efficacy in… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2014
2014
Rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin G2 against hepatocyte growth factor (HGF) that… (More)
Is this relevant?
2014
2014
OBJECTIVE This open-label, multi-institutional phase II trial evaluated activity and safety of rilotumumab (AMG 102), a… (More)
Is this relevant?
2013
2013
PURPOSE To evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
This phase II study evaluated the efficacy and safety of AMG 102 (rilotumumab), a fully human monoclonal antibody against… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2009
2009
Tyrosine kinase receptors and their ligands have become appealing candidates as molecular therapeutic agents for the treatment of… (More)
Is this relevant?